Life's Little Mysteries, part 2
Further to this post I now have a biopsy result. Earlier today, my specialist's advised me I have Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
When asked about its aggressiveness… advised it is totally non-agressive and is an uncommon subtype of Hodgkin lymphoma (HL). This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (CHL), by characteristic pathologic and clinical features.
NLPHL represents a more indolent disease than CHL, and is therefore managed uniquely. Since this disease is rare, most information concerning treatment and outcome has come from reports of single institutions or pooled, multi-institutional retrospective analyses.
When asked about its aggressiveness… advised it is totally non-agressive and is an uncommon subtype of Hodgkin lymphoma (HL). This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (CHL), by characteristic pathologic and clinical features.
NLPHL represents a more indolent disease than CHL, and is therefore managed uniquely. Since this disease is rare, most information concerning treatment and outcome has come from reports of single institutions or pooled, multi-institutional retrospective analyses.
It is their understanding that patients with NLPHL may not require as aggressive therapies and that the treatment standard of chemotherapy followed by involved-field RT that has been used in CHL may not be appropriate for NLPHL. So for the time being, it is my choice to watch and wait...
Comments